Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Moderate Buy” by Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $20.71.

Several analysts recently issued reports on the company. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 26th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, March 26th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Thursday, April 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Thursday, April 4th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday, March 26th.

Insider Buying and Selling at Stoke Therapeutics

In other news, CEO Edward M. Md Kaye sold 11,150 shares of the business’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares in the company, valued at $423,035. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the sale, the chief executive officer now directly owns 69,350 shares of the company’s stock, valued at $423,035. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Stephen J. Tulipano sold 4,116 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the transaction, the chief financial officer now directly owns 20,746 shares of the company’s stock, valued at approximately $126,550.60. The disclosure for this sale can be found here. Insiders have sold a total of 3,622,741 shares of company stock worth $41,935,115 over the last 90 days. Insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds have recently modified their holdings of the business. Lynx1 Capital Management LP acquired a new position in Stoke Therapeutics during the 3rd quarter valued at $6,738,000. GSA Capital Partners LLP increased its holdings in shares of Stoke Therapeutics by 514.7% during the 3rd quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock worth $1,371,000 after purchasing an additional 291,443 shares during the period. Birchview Capital LP raised its position in shares of Stoke Therapeutics by 147.1% during the fourth quarter. Birchview Capital LP now owns 210,000 shares of the company’s stock valued at $1,105,000 after buying an additional 125,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Stoke Therapeutics by 9.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock valued at $576,000 after buying an additional 12,478 shares during the period. Finally, Trexquant Investment LP grew its position in Stoke Therapeutics by 166.9% during the third quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock worth $503,000 after buying an additional 79,785 shares in the last quarter.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $12.02 on Wednesday. The firm has a market capitalization of $626.48 million, a price-to-earnings ratio of -5.07 and a beta of 0.82. The company has a 50 day simple moving average of $10.05 and a 200-day simple moving average of $6.57. Stoke Therapeutics has a 52-week low of $3.35 and a 52-week high of $16.40.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.02. The company had revenue of $2.80 million during the quarter, compared to analysts’ expectations of $3.70 million. On average, analysts predict that Stoke Therapeutics will post -2.28 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.